Tecan Group AG

BATS-CHIXE:TECNZ Stock Report

Market Cap: CHF 2.7b

Tecan Group Valuation

Is TECNZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TECNZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TECNZ (CHF210) is trading below our estimate of fair value (CHF235.82)

Significantly Below Fair Value: TECNZ is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TECNZ?

Key metric: As TECNZ is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for TECNZ. This is calculated by dividing TECNZ's market cap by their current earnings.
What is TECNZ's PE Ratio?
PE Ratio26.6x
EarningsCHF 101.34m
Market CapCHF 2.70b

Price to Earnings Ratio vs Peers

How does TECNZ's PE Ratio compare to its peers?

The above table shows the PE ratio for TECNZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average54.2x
ERGO Ergomed
46.7x14.2%UK£701.1m
HVO hVIVO
8.5x-15.2%UK£148.0m
HIK Hikma Pharmaceuticals
19x12.7%UK£4.3b
GNS Genus
142.7x37.7%UK£1.1b
TECNZ Tecan Group
26.6x14.9%CHF 2.7b

Price-To-Earnings vs Peers: TECNZ is good value based on its Price-To-Earnings Ratio (26.6x) compared to the peer average (56.7x).

Price to Earnings Ratio vs Industry

How does TECNZ's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
No. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: TECNZ is good value based on its Price-To-Earnings Ratio (26.6x) compared to the European Life Sciences industry average (36.8x).

Price to Earnings Ratio vs Fair Ratio

What is TECNZ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TECNZ PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio26.6x
Fair PE Ratio23.9x

Price-To-Earnings vs Fair Ratio: TECNZ is expensive based on its Price-To-Earnings Ratio (26.6x) compared to the estimated Fair Price-To-Earnings Ratio (23.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TECNZ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 210.00
CHF 286.14
+36.3%
15.6%CHF 384.00CHF 241.00n/a7
Nov ’25CHF 220.80
CHF 295.29
+33.7%
15.5%CHF 384.00CHF 241.00n/a7
Oct ’25CHF 275.60
CHF 348.75
+26.5%
11.0%CHF 415.00CHF 300.00n/a8
Sep ’25CHF 285.20
CHF 351.71
+23.3%
11.4%CHF 415.00CHF 300.00n/a7
Aug ’25CHF 326.80
CHF 385.71
+18.0%
8.2%CHF 415.00CHF 330.00n/a7
Jul ’25CHF 300.40
CHF 396.57
+32.0%
5.8%CHF 418.00CHF 347.00n/a7
Jun ’25CHF 320.90
CHF 397.71
+23.9%
6.0%CHF 420.00CHF 347.00n/a7
May ’25CHF 330.20
CHF 395.57
+19.8%
7.2%CHF 420.00CHF 332.00n/a7
Apr ’25CHF 374.00
CHF 397.14
+6.2%
7.1%CHF 420.00CHF 332.00n/a7
Mar ’25CHF 349.20
CHF 390.86
+11.9%
10.5%CHF 450.00CHF 311.00n/a7
Feb ’25CHF 329.60
CHF 392.29
+19.0%
10.6%CHF 450.00CHF 311.00n/a7
Jan ’25CHF 342.80
CHF 412.50
+20.3%
14.8%CHF 480.00CHF 300.00n/a6
Dec ’24CHF 311.60
CHF 435.00
+39.6%
8.7%CHF 480.00CHF 372.00n/a5
Nov ’24CHF 266.40
CHF 447.40
+67.9%
4.9%CHF 480.00CHF 417.00CHF 220.805
Oct ’24CHF 309.20
CHF 447.83
+44.8%
4.4%CHF 480.00CHF 417.00CHF 275.606
Sep ’24CHF 353.20
CHF 448.86
+27.1%
4.1%CHF 480.00CHF 417.00CHF 285.207
Aug ’24CHF 347.40
CHF 466.86
+34.4%
2.8%CHF 485.00CHF 450.00CHF 326.807
Jul ’24CHF 343.20
CHF 463.83
+35.1%
2.6%CHF 480.00CHF 450.00CHF 300.406
Jun ’24CHF 349.80
CHF 464.83
+32.9%
2.4%CHF 480.00CHF 450.00CHF 320.906
May ’24CHF 388.60
CHF 461.80
+18.8%
2.2%CHF 480.00CHF 450.00CHF 330.205
Apr ’24CHF 398.80
CHF 460.33
+15.4%
4.3%CHF 485.00CHF 425.00CHF 374.006
Mar ’24CHF 377.40
CHF 459.00
+21.6%
5.0%CHF 483.00CHF 425.00CHF 349.205
Feb ’24CHF 384.80
CHF 470.00
+22.1%
4.2%CHF 493.00CHF 440.00CHF 329.604
Jan ’24CHF 413.40
CHF 470.00
+13.7%
4.2%CHF 493.00CHF 440.00CHF 342.804
Dec ’23CHF 400.40
CHF 467.50
+16.8%
3.6%CHF 483.00CHF 440.00CHF 311.604
Nov ’23CHF 355.80
CHF 467.50
+31.4%
3.6%CHF 483.00CHF 440.00CHF 266.404

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Regeneron Pharmaceuticals

US$81.2b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$742.70

7D

-0.8%

1Y

-8.6%

hVIVO

UK£146.3m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.22

7D

-1.1%

1Y

6.4%

Hikma Pharmaceuticals

UK£4.3b

Develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products.

HIKL

UK£19.41

7D

4.0%

1Y

12.9%